This study is currently not recruiting participants.

INCB18424-266; A Randomized Double-Blind Phase 2 Study of Ruxolitinib or Placebo in Combination With Pemetrexed/Cisplatin and Pemetrexed Maintenance for Initial Treatment of Subjects With Nonsquamous Non-Small Cell Lung Cancer That Is Stage IIIB Stage IV or Recurrent

Investigation of an Investigational Medication with Cancer Treatment for Advanced Lung Cancer

Not Recruiting
18 years - 75 years
All
Phase N/A

Brief description of study.

The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Detailed description of study

The purpose of this study is to determine if ruxolitinib, in combination with Pemetrexed/Cisplatin and Pemetrexed Maintenance, is safe and effective in the treatment of nonsquamous non-small cell lung cancer (NSCLC) that is Stage IIIB, Stage IV, or recurrent.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: carcinoma
  • Age: 18 years - 75 years
  • Gender: All

This study investigates the safety and effectiveness of an investigational medication combined with chemotherapy in treating nonsquamous non-small cell lung cancer (NSCLC) at advanced stages, including Stage IIIB, Stage IV, or recurrent cases. NSCLC is a type of lung cancer that is not small cell and is characterized by the way the cancer cells look under a microscope.

Participants will receive a combination of treatments, including an investigational medication with Pemetrexed and Cisplatin, followed by Pemetrexed maintenance therapy. Pemetrexed and Cisplatin are chemotherapy drugs used to treat lung cancer, and maintenance therapy helps to keep the cancer from coming back after it has responded to initial treatment.

  • Who can participate: Participants must be adults diagnosed with advanced nonsquamous non-small cell lung cancer. Key eligibility factors include age over 18 and specific health criteria related to lung cancer stage and previous treatments.
  • Study details: Participants will receive an investigational medication along with chemotherapy drugs Pemetrexed and Cisplatin, followed by Pemetrexed maintenance therapy.
Updated on 19 Feb 2024. Study ID: 1405186689 (20140650)

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team